Gut microbiota-generated metabolite, trimethylamine-N-oxide, and subclinical myocardial damage: a multicenter study from Thailand

Vichai Senthong1, Songsak Kiatchoosakun2, Chaiaysith Wongvipaporn1, Jutarop Phetcharaburarin2,3, Pyatat Tatsanavivat1, Piyamitr Sritara4 & Arintaya Phrommintikul5

Plasma Trimethylamine-N-oxide (TMAO), a gut microbiota metabolite from dietary phosphatidylcholine, is mechanistically linked to cardiovascular disease (CVD) and adverse cardiovascular events. We aimed to examine the relationship between plasma TMAO levels and subclinical myocardial damage using high-sensitivity cardiac troponin-T (hs-cTnT). We studied 134 patients for whom TMAO data were available from the Cohort Of patients at a high Risk of Cardiovascular Events—Thailand (CORE-Thailand) registry, including 123 (92%) patients with established atherosclerotic disease and 11 (8%) with multiple risk factors. Plasma TMAO was measured by NMR spectroscopy. In our study cohort (mean age 64 ± 8.9 years; 61% men), median TMAO was 3.81 μM (interquartile range [IQR] 2.89–5.50 μM), and median hs-cTnT was 15.65 ng/L (IQR 10.17–26.67). Older patients and those with diabetic or hypertension were more likely to have higher TMAO levels. Plasma TMAO levels correlated with those of hs-cTnT (r = 0.54; p < 0.0001) and were significantly higher in patients with subclinical myocardial damage (hs-cTnT ≥ 14 ng/L; 4.48 μM vs 2.98 μM p < 0.0001). After adjusting for traditional risk factors, elevated TMAO levels remained independently associated with subclinical myocardial damage (adjusted odds ratio [OR]: 1.58; 95% CI 1.24–2.08; p = 0.0007). This study demonstrated that plasma TMAO was an independent predictor for subclinical myocardial damage in this study population.

Abbreviations

CAD  Coronary artery disease
CVD  Cardiovascular disease
TMAO  Trimethylamine-N-oxide
hs-cTnT  High-sensitivity cardiac troponin T
SMD  Subclinical myocardial damage

Trimethylamine-N-oxide (TMAO) is a gut microbiota metabolite from dietary phosphatidylcholine (PC) which present in red meat, egg yolks and liver. Increasing data support the role TMAO in the pathogenesis of cardiovascular disease (CVD)1–5. Importantly, elevated plasma TMAO levels are correlated with future risk of adverse cardiovascular events, increased CVD prevalence, number of diseased coronary vessels and atherosclerotic burden of coronary artery disease (CAD)2,6,7.

1Cardiovascular Unit, Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand. 2Department of Biochemistry, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand. 3Khon Kaen University International Phenome Laboratory, Northeastern Science Park, Khon Kaen University, Khon Kaen, Thailand. 4Cardiovascular Unit, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. 5Cardiovascular Unit, Department of Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand. *email: arintaya.p@cmu.ac.th
High sensitivity cardiac troponin is a sensitive and specific biomarker of myocardial damage and has been used in the clinical diagnosis of myocardial infarction in acute coronary syndrome (ACS). Assays to detect circulating high-sensitivity cardiac troponin (either T or I) allow for the robust detection of very low troponin concentrations, an indicator of subclinical myocardial damage (SMD) in asymptomatic patients. Several studies have shown a link between SMD and future risk of adverse cardiovascular events in stable patients with and without CVD, particularly in the general population.

Several studies have demonstrated the mechanisms underlying the link between elevated plasma TMAO and CVD pathogenesis/risk of cardiovascular events. We thus sought to examine the relationship between plasma TMAO levels and high-sensitivity cardiac troponin T (hs-cTnT) in stable patients at high risk of cardiovascular events.

### Results

**Patient characteristics.** Overall baseline characteristics of the 134 patients in the study population are shown in Table 1. The mean age was 64 years, 61% were men, 40% had diabetes, 123 (92%) had established atherosclerotic disease (EAD), and 11 (8%) had multiple risk factors (MRFs). Median TMAO was 3.81 μM (Interquartile range [IQR] 2.89–5.50 μM), and hs-cTnT was 15.65 ng/L (IQR 10.17–26.67).

Baseline characteristics were stratified according to presence of SMD. Overall, there were 77 (57%) patients with SMD (hs-cTnT ≥ 14 ng/L). Those with evidence of SMD were more likely to be male, and a slightly higher percentage used angiotensin converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB). By contrast, history of hypertension, diabetes, EAD status, and renal function did not differ by SMD status. Interestingly, SMD was significantly associated with higher TMAO levels (4.48 μM, [IQR: 3.45–6.14] vs 2.98 μM [IQR: 2.31–4.23]; p < 0.0001).

**Plasma TMAO levels and subclinical myocardial damage.** Plasma TMAO was strongly correlated with hs-cTnT (Pearson correlation; r = 0.54, p < 0.0001) (Fig. 1), and TMAO levels were significantly higher in patients with evidence of SMD (Fig. 2). In univariate logistic regression analysis, plasma TMAO levels, male, EAD, estimated glomerular filtration rate (eGFR), and ACEI/ARB use were significantly associated with SMD (Table 2).

| Variables                  | Overall (N = 134) | Subclinical myocardial necrosis (SMN) | P value |
|----------------------------|-------------------|--------------------------------------|---------|
| Age, (year)                | 64.05 (8.9)       | 63.6 (8.4)                            | 0.53    |
| Male sex, (%)              | 82 (61.2)         | 56 (72.7)                             | 0.001   |
| BMI (kg/m²)                | 24.62 (4.19)      | 24.85 (4.02)                          | 0.47    |
| Systolic BP, (mm Hg)       | 131.49 (19.45)    | 132.74 (18.89)                        | 0.39    |
| Diastolic BP, (mm Hg)      | 73.1 (9.52)       | 73.91 (9.61)                          | 0.25    |
| Heart rate (beat per min)  | 73.6 (12.97)      | 74.16 (13.8)                          | 0.56    |
| Coronary Artery Disease (%)| 123 (91.4)        | 71 (92.2)                             | 0.99    |
| History of myocardial infarction (%) | 99 (73.9)   | 60 (77.9)                             | 0.22    |
| Percutaneous coronary intervention (%) | 100 (74.6) | 61 (79.2)                             | 0.16    |
| Coronary artery bypass graft surgery (%) | 4 (3.0)      | 2 (2.6)                              | 0.99    |
| Diabetes mellitus (%)      | 53 (39.6)         | 33 (42.9)                             | 0.36    |
| Hypertension (%)           | 67 (50.0)         | 38 (49.4)                             | 0.86    |
| Current smoker status      | 8 (6.0)           | 5 (6.5)                               | 0.99    |
| hs-cTnT (ng/L)             | 15.65 (10.17–26.67) | 24.4 (17.9–37.2)                  | <0.001  |
| Dyslipidemia (%)           | 53 (39.6)         | 75 (97.4)                             | 0.99    |
| eGFR (ml/min/1.73 m²)      | 72.4 (51.7–88.55) | 73.6 (49.8–88.1)                     | 0.67    |
Elevated TMAO remained a significant predictor of SMD after multivariate logistic regression analysis, which adjusted for traditional risk factors (age, male, smoking, dyslipidemia, diabetes, hypertension, body mass index and eGFR), EAD status, and ACEI/ARB use (adjusted odds ratio [OR] 1.58; 95% CI 1.24–2.08, p = 0.0007; Table 2). By contrast, EAD, eGFR, and ACEI/ARB use were no longer significant predictors of SMD.

We further examined the association of TMAO and SMD using multiple logistic regression analysis, adjusting for any variable with a p-value < 0.3 according to univariate analysis including age, male, eGFR, EAD status, and ACEI/ARB use. Interestingly, elevated TMAO remained a significant predictor of SMD (adjusted OR 1.55; 95% CI 1.23–2.04, p = 0.0007; Table 3).

To our knowledge, this is the first report of elevated plasma TMAO as an independent predictor of SMD (quantified as hs-cTnT ≥ 14 ng/L) in stable patients at high risk of cardiovascular events (123 [92%] with EAD and 11 [8%] with MRFs). The prevalence of SMD in our study cohort was 57%, despite our including stable patients without evidence of ACS at presentation. The key finding of our study is the strong significant association between fasting plasma TMAO levels and SMD. Furthermore, elevated TMAO was an independent predictor of SMD, even following adjustment for traditional risk factors, EAD status, and ACEI/ARB use.

TMAO, a gut microbiota-generated metabolite, plays an important role in global metabolism. Recent reports have shown that increased levels of plasma TMAO are associated with adverse cardiovascular outcomes and have a direct mechanistic link to the development of CVD. This is consistent with several other recent studies in

Figure 1. Correlation between plasma TMAO levels and high-sensitivity cardiac troponin-T.

Figure 2. Relationship between plasma TMAO levels and subclinical myocardial damage.
subsets of stable patients with elective coronary angiography, peripheral artery disease, diabetes mellitus, chronic kidney disease, CAD, history of heart failure (HF), and even those without CVD1–3,5,7,15. Interestingly, another previous study found elevated TMAO to be associated with risk of major adverse cardiac events among patients with suspected ACS who were initially negative for cardiac troponin T (< 0.1 ng/mL)16. Moreover, elevated TMAO can predict the presence of coronary atherosclerotic burden and complexity as defined by SYNTAX score and diffuse lesion characteristics6. These findings were independent of traditional risk factors and were validated by independent cohorts, which were reviewed in a recent meta-analyses17. However, the association between TMAO and evidence of SMD as indicated by higher hs-cTnT, has not been well explored. This was the first study to show elevated plasma TMAO to be an independent predictor of SMD. This is consistent with the gut microbiota TMAO pathway being mechanistically linked with the development of atherosclerosis and adverse prognosis.

Detection of circulating hs-cTnT is associated with myocardial damage and is a recommended diagnostic criterion for myocardial infarction in ACS18. There is evidence that low hs-cTnT concentration in subjects without clinical setting of ACS indicates an increased risk of future cardiovascular events and may predict poor prognosis10,18. Low hs-cTnT concentration is a useful biomarker to stratify patients by risk level (both in stable CVD patients and in the general population)9,11,13. In stable patients with chronic HF or stable CAD, higher hs-cTnT is associated with increased risk of cardiovascular events10,12. Previous studies have shown that low hs-cTnT is associated with higher incidence of cardiovascular events, total mortality, and cardiac abnormalities (e.g., left ventricular hypertrophy, left atrial enlargement, and silent ischemia) in the general population9,12.

In our study cohort, we defined SMD as hs-cTnT ≥ 14 ng/L, which is the 99th percentile cut-point for diagnosis of myocardial infarction. Importantly, although we included stable patients without evidence of ACS at presentation, elevated plasma TMAO was associated with SMD. Moreover, while hs-cTnT is often higher in patients with declining of renal function16, elevated plasma TMAO remained an independent predictor of SMD even after adjusting for eGFR and other potentially confounding factors. Therefore, it is conceivable that SMD may occur

|   | Univariate Analysis |   | Multivariate Analysis |
|---|---------------------|---|-----------------------|
|   | OR (95% CI) | P value | Adjusted OR* (95% CI) | P value | VIF |
| TMAO | 1.84 (1.22–1.92) | <0.0001 | 1.58 (1.24–2.08) | 0.007 | 1.05 |
| Age | 0.99 (0.94–1.04) | 0.67 | 0.99 (0.94–1.04) | 0.67 | 1.48 |
| Male | 3.18 (1.54–6.56) | 0.02 | 3.68 (1.55–7.20) | 0.004 | 1.22 |
| BMI | 1.03 (0.95–1.12) | 0.47 | 0.69 (0.02–10.5) | 0.74 | 1.39 |
| Dyslipidemia | 1.12 (0.47–2.76) | 0.78 | 0.89 (0.36–2.16) | 0.79 | 1.06 |
| Diabetes mellitus | 0.72 (0.36–1.46) | 0.36 | 0.96 (0.38–2.40) | 0.78 | 1.22 |
| Hypertension | 1.01 (0.99–1.03) | 0.39 | 1.27 (0.44–3.71) | 0.66 | 1.09 |
| Smoking | 0.8 (0.83–3.49) | 0.78 | 1.14 (0.19–7.13) | 0.88 | 1.10 |
| Established CVD | 0.54 (0.21–1.36) | 0.19 | 1.45 (0.31–6.74) | 0.63 | 1.08 |
| eGFR | 0.99 (0.98–1.01) | 0.18 | 0.98 (0.96–1.0) | 0.89 | 1.45 |
| Statin | 0.75 (1.32–16.9) | 0.75 | − | − | − |
| ACEI/ARB | 0.4 (0.19–0.83) | 0.014 | 2.03 (0.87–4.87) | 0.10 | 1.01 |
| Antiplatelet | 0.42 (0.09–1.84) | 0.25 | − | − | − |

Table 3. Adjusted odds ratios (OR) using variables with P-value < 0.3 based on univariate analysis. Abbreviations as in Table 2.

| Subclinical myocardial damage (hs-cTnT ≥ 14 ng/L) |  |
|---|---|---|
|   | OR (95% CI) | P value | VIF |
| Adjusted TMAO | 1.55 (1.23–2.04) | 0.0007 | 1.01 |
| Age | 0.97 (0.84–1.12) | 0.61 | 1.38 |
| Male | 3.24 (1.40–4.36) | 0.001 | 1.15 |
| eGFR | 0.98 (0.97–1.00) | 0.11 | 1.15 |
| ACEI/ARB | 2.08 (0.93–4.76) | 0.08 | 1.00 |
| Established CVD | 1.40 (0.72–2.18) | 0.74 | 1.06 |
in with elevated plasma TMAO. This may be a clue to understanding the underlying mechanism through which elevated plasma TMAO is linked to enhanced risk of CVD and poor prognosis.

Previous studies have consistently demonstrated that the TMAO pathway is linked mechanistically to multiple cardiovascular and metabolic processes with CVD pathogenesis including the development of atherosclerotic plaque, promotion of adipose tissue inflammation, alteration in macrophage and endothelial cells, plasma lipid abnormalities, insulin resistance, obesity, and enhanced platelet hyperactivity and thrombosis risk, all of which contribute to SMD due to troponin leak1–6,17,21–23.

TMAO may exhibit direct biological activity in modulating platelet hyperactivity, which increases the risk of thrombus formation24,25. Several recent studies have demonstrated that flavin-containing monooxygenase 3 (FMO3), the major host enzyme responsible for converting gut microbiota-generated trimethylamine (TMA) into TMAO, is an important regulator of sterol metabolism, prevents reverse cholesterol transport, and is linked to the development of atherosclerosis21,22. By contrast, FMO3 knockout mice had decreased circulating TMAO levels and attenuated atherosclerosis plaque formation25. Moreover, recent studies have found that a high fat diet plus 0.2% TMAO promotes adipose tissue inflammation in mice, which be related to SMD26.

Our findings shed light on a potential pathophysiological contribution of gut microbiota in the development of atherosclerosis and to adverse prognosis in patients with high atherosclerotic risk. Further study is needed to determine whether therapeutic strategies that reduce plasma TMAO levels can also improve prognosis in these patients.

Study limitations. This study had the following limitations: first, only patients with available TMAO data were included, which may have led to selection bias. Second, despite all subjects being recruited from the outpatient clinic after fasting for at least 8 h, we could not exclude the potential for dietary intake of PC or TMAO within 24 h before blood sampling. Third, because plasma TMAO and hs-cTnT were measured at only one point in time, we were unable to evaluate the prognostic value of changes in these indicators. Finally, a relatively low number of patients with MRFs were included in this study.

Conclusions

Fasting plasma TMAO is an independent predictor of SMD in patients with high atherosclerotic risk. These findings are consistent with numerous previous studies that have demonstrated a link between elevated plasma TMAO and atherosclerosis pathogenesis and cardiovascular risk. Further study into the mechanism by which elevated TMAO leads to SMD is warranted.

Subjects and methods

The Cohort Of patients at a high Risk of Cardiovascular Events—Thailand (CORE—Thailand) registry is a prospective, multicenter, longitudinal cohort study of Thai patients with high atherosclerotic risk. This includes patients aged 45 years or older with EAD and those with MRFs, as detailed in previous publications27.

We studied 134 patients for whom TMAO data were available. This study was approved by the Khon Kaen University Ethics Committee for Human Research (HE611011) and was conducted in accordance with the Declaration of Helsinki.

Laboratory testing. Informed consent was obtained from all patients and fasting blood samples were collected using EDTA tubes at the time of hospital visit. These were then immediately processed and frozen at −80 °C until analysis. Plasma TMAO levels were determined using an NMR spectrometer at 400 MHz (Bruker, USA). The Carr-Purcell-Meiboom-Gill (CPMG) pulse sequence was employed to obtain spectra (recycle delay-90°-t1-90°-tm-90°-acquisition) over 64 scans with four dummy scans. Quantification was achieved using a concentration of a known reference signal (in this case TSP) to determine the TMAO concentration. hs-cTnT was measured using a high-sensitivity (5th generation) assay on a Roche Cobas e411 platform (Roche Diagnostics, Basel, Switzerland). We defined SMD as hs-cTnT ≥14 ng/L, as this is considered the upper limit (the 99th percentile) of the normal range in the healthy population19. eGFR was calculated using the modification of diet in renal disease (MDRD) equation.

Statistical analysis. Continuous data are presented as means (standard deviation) or medians (interquartile range) and compared with a student’s t-test or non-parametric test (Mann–Whitney U Test) as appropriate. Categorical variables are presented as numbers (%) and compared between groups using a chi-square test. The correlations between hs-cTnT and plasma TMAO-associated factors were analyzed using the multicollinearity index. Comparisons among three or more groups were evaluated using one-way analysis of variance (ANOVA) or the Kruskal–Wallis test depending on whether or not the distribution was normal. Univariate and multivariate logistic regression analysis was used to determine independent predictors of SMD. Variables entered into the multivariate model included traditional risk factors (age, male, smoking, dyslipidemia, diabetes, hypertension, body mass index, and eGFR), ACEI/ARB use, and EAD status. All analyses were performed using R version 4.0.3. A p value <0.05 was considered statistically significant.

Received: 21 May 2021; Accepted: 30 June 2021
Published online: 22 July 2021

References

1. Kanitsoraphan, C., Rattanawong, P., Charoenru, S. & Senthong, V. Trimethylamine N-oxide and risk of cardiovascular disease and mortality. Curr. Nutr. Rep. 7, 207–213. https://doi.org/10.1007/s13668-018-0252-z (2018).
2. Tang, W. H. et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. *N. Engl. J. Med.* **368**, 1575–1584. https://doi.org/10.1056/NEJMoa1009400 (2013).

3. Wang, Z. et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. *Nature* **472**, 57–63. https://doi.org/10.1038/nature09922 (2011).

4. Wang, Z. et al. Prognostic value of choline and betaine depends on intestinal microbiota-generated metabolite trimethylamine-N-oxide. *Eur. Heart J.* **35**, 904–910. https://doi.org/10.1093/eurheartj/ehu002 (2014).

5. Tang, W. H., Køller, M., Bäckhed, F., Landmesser, U. & Hazen, S. L. Intestinal microbiota in cardiovascular health and disease: JACC state-of-the-art review. *J. Am. Coll. Cardiol.* **73**, 2089–2105. https://doi.org/10.1016/j.jacc.2019.03.024 (2019).

6. Senthong, V. et al. Plasma trimethylamine N-oxide, a gut microbe-generated phosphatidylcholine metabolite, is associated with atherosclerotic burden. *J. Am. Coll. Cardiol.* **67**, 2620–2628. https://doi.org/10.1016/j.jacc.2016.03.546 (2016).

7. Senthong, V. et al. Intestinal microbiota-generated metabolite trimethylamine-N-oxide and 5-year mortality risk in stable coronary artery disease: The contributory role of intestinal microbiota in a COURAGE-like patient cohort. *J. Am. Heart Assoc.* https://doi.org/10.1161/jaha.115.002816 (2016).

8. Collet, J. P. et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. *Eur. Heart J.* **42**, 1289–1367. https://doi.org/10.1093/eurheartj/ehaa575 (2021).

9. de Lemos, J. A., Wang, Z., Tang, W. H. & Minassian, A. A. Association of troponin T levels with cardiovascular risk in the general population. *JAMA* **304**, 2503–2512. https://doi.org/10.1001/jama.2010.1768 (2010).

10. Omland, T. et al. A sensitive cardiac troponin T assay in stable coronary artery disease. *N. Engl. J. Med.* **361**, 2538–2547. https://doi.org/10.1056/NEJMoa0805299 (2009).

11. Lam, C. S. P. et al. High-sensitivity troponin I for cardiovascular risk stratification in the general asymptomatic population: Perspectives from Asia-Pacific. *Int. J. Cardiol.* **282**, 93–98. https://doi.org/10.1016/j.ijcard.2019.01.107 (2019).

12. Latini, R. et al. Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. *Circulation* **116**, 1242–1249. https://doi.org/10.1161/circulationaha.106.655076 (2007).

13. Linnemann, B. et al. Elevated cardiac troponin T is associated with higher mortality and amputation rates in patients with peripheral arterial disease. *J. Am. Coll. Cardiol.* **63**, 1529–1538. https://doi.org/10.1016/j.jacc.2013.05.059 (2014).

14. Wallace, T. W. et al. Prevalence and determinants of troponin T elevation in the general population. *Circulation* **113**, 1958–1965. https://doi.org/10.1161/circulationaha.105.609974 (2006).

15. Senthong, V. et al. Trimethylamine N-oxide and mortality risk in patients with peripheral artery disease. *J. Am. Heart Assoc.* https://doi.org/10.1161/jaha.116.004237 (2016).

16. Li, X. S. et al. Gut microbiota-dependent trimethylamine N-oxide in acute coronary syndromes: A prognostic marker for incident cardiovascular events beyond traditional risk factors. *Eur. Heart J.* **38**, 814–824. https://doi.org/10.1093/eurheartj/ehw582 (2017).

17. Heianza, Y., Ma, W., Manson, J. E., Rexrode, K. M. & Qi, L. Gut microbiota metabolites and risk of major adverse cardiovascular disease events and death: A systematic review and meta-analysis of prospective studies. *J. Am. Heart Assoc.* https://doi.org/10.1161/jaha.116.004947 (2017).

18. Thygensen, K. et al. Fourth universal definition of myocardial infarction (2018). *J. Am. Coll. Cardiol.* **72**, 2231–2264. https://doi.org/10.1016/j.jacc.2018.08.1038 (2018).

19. Sanders, J. T. et al. Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. *Circulation* **123**, 1367–1376. https://doi.org/10.1161/circulationaha.110.005264 (2011).

20. Khan, N. A., Hemmelgarn, B. R., Tonelli, M., Thompson, C. R. & Levin, A. Prognostic value of troponin T and I among asymptomatic patients with end-stage renal disease: A meta-analysis. *Circulation* **112**, 3088–3096. https://doi.org/10.1161/circulationaha.105.560128 (2005).

21. Koeth, R. A. et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. *Nat. Med.* **19**, 576–585. https://doi.org/10.1038/nm.3145 (2013).

22. Koeth, R. A. et al. γ-Butyrobetaine is a proatherogenic intermediate in gut microbial metabolism of L-carnitine to TMAO. *Cell Metab.* **20**, 799–812. https://doi.org/10.1016/j.cmet.2014.10.006 (2014).

23. Zha, W. et al. Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk. *Cell* **165**, 111–124. https://doi.org/10.1016/j.cell.2016.02.011 (2016).

24. Warrier, M. et al. The TMAO-generating enzyme flavin monooxygenase 3 is a central regulator of cholesterol balance. *Cell Rep.* **10**, 326–338. https://doi.org/10.1016/j.celrep.2014.12.036 (2015).

25. Shih, D. M. et al. Flavin containing monooxygenase 3 exerts broad effects on glucose and lipid metabolism and atherosclerosis. *J. Lipid Res.* **56**, 22–37. https://doi.org/10.1194/jlr.M051680 (2015).

26. Gao, X. et al. Dietary trimethylamine N-oxide exacerbates impaired glucose tolerance in mice fed a high fat diet. *J. Biosci. Bioeng.* **118**, 476–481. https://doi.org/10.1016/j.jbiosc.2014.03.001 (2014).

27. Phrommintikul, A. et al. Management of atherosclerosis risk factors for patients at high cardiovascular risk in real-world practice: a multicentre study. *Singapore Med. J.* **58**, 535–542. https://doi.org/10.1162/smedj.2017044 (2017).

Acknowledgements

The authors acknowledge the contribution of the CORE investigators. We also acknowledge Dr. Dylan Southard for editing this MS via the KKU Publication Clinic and Asst. Prof. Anupol Panitchote for statistical analysis.

Author contributions

VS, wrote the main manuscript, helped to run TMAO levels and manuscript submitted. S.K. Critical reading. C.W. Critical reading. J.P. Run TMAO levels. P.T. Critical reading. P.S. Critical reading. A.P. Revise manuscript, critical reading, final approval.

Funding

This research was supported by the Heart Association of Thailand under the Royal Patronage of H.M. the King, National Research Council of Thailand.

Competing interests

The authors declare no competing interests.

Additional information

Correspondence and requests for materials should be addressed to A.P.

Reprints and permissions information is available at www.nature.com/reprints.
Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021